Warfarin-associated hemorrhage and cerebral amyloid angiopathy
A genetic and pathologic study
Abstract
Background: Intracerebral hemorrhage (ICH) is the most feared complication of warfarin therapy. The pathogenesis of this often-fatal complication remains obscure. Cerebral amyloid angiopathy (CAA) is a major cause of spontaneous lobar hemorrhage in the elderly and is associated with specific alleles of the APOE gene.
Objective: To assess the role of CAA in warfarin-associated ICH.
Methods: Clinical characteristics and APOE genotype were compared between 41 patients with warfarin-related ICH (from a cohort of 59 consecutive patients aged ≥65 years with supratentorial ICH on warfarin) and 66 randomly selected individuals aged ≥65 years without ICH taking warfarin. In addition, all neuropathologic specimens from ICH patients were reviewed for the presence and severity of CAA.
Results: Hemorrhages tended to be in the lobar regions of the brain, and most (76%) occurred with an international normalized ratio of ≤3.0. The APOE ε2 allele was overrepresented among patients with warfarin-associated lobar hemorrhage (allele frequency 0.13 versus 0.04 in control subjects; p = 0.031). After controlling for other variables associated with ICH, carriers of the ε2 allele had an OR of 3.8 (95% CI, 1.0 to 14.6) for lobar ICH. CAA was pathologically diagnosed as the cause of lobar hemorrhage in 7 of 11 patients with available tissue samples.
Conclusions: CAA is an important cause of warfarin-associated lobar ICH in the elderly. Although diagnosis of CAA before hemorrhage is not yet possible, these data offer hope that future patients at high risk for hemorrhage may be identified before initiation of warfarin therapy.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke . 1995; 26: 1471–1477.
2.
Gustafsson C, Asplund K, Britton M, Norrving B, Olsson B, Marke LA. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. Br Med J . 1992; 305: 1457–1460.
3.
Albers GW. Atrial fibrillation and stroke. Three new studies, three remaining questions. Arch Intern Med . 1994; 154: 1443–1448.
4.
Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet . 1994; 343: 687–691.
5.
Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med . 1996; 156: 409–416.
6.
Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet . 1996; 348: 633–638.
7.
Stroke Prevention in Reversible Ischemia Trial Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol . 1997; 42: 857–865.
8.
Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med . 1989; 87: 144–152.
9.
Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med . 1994; 120: 897–902.
10.
Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest . 1998; 114 (suppl): 511S–523S.
11.
Gorter JW. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention in Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology . 1999; 53: 1319–1327.
12.
Okazaki H, Reagan TJ, Campbell RJ. Clinicopathologic studies of primary cerebral amyloid angiopathy. Mayo Clin Proc . 1979; 54: 22–31.
13.
Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke . 1987; 18: 311–324.
14.
Melo TP, Bogousslavsky J, Regli F, Janzer R. Fatal hemorrhage during anticoagulation of cardioembolic infarction: role of cerebral amyloid angiopathy. Eur Neurol . 1993; 33: 9–12.
15.
Sloan MA, Price TR, Petito CK, et al. Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II pilot and randomized clinical trial combined experience. Neurology . 1995; 45: 649–658.
16.
Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science . 1988; 240: 622–630.
17.
Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science . 1993; 261: 921–923.
18.
Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet . 1994; 7: 180–184.
19.
Greenberg SM, Rebeck GW, Vonsattel JPV, Gomez–Isla T, Hyman BT. Apolipoprotein E ε4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol . 1995; 38: 254–259.
20.
Premkumar DR, Cohen DL, Hedera P, Friedland RP, Kalaria RN. Apolipoprotein E-ε4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer’s disease. Am J Pathol . 1996; 148: 2083–2095.
21.
Nicoll JA, Burnett C, Love S, et al. High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann Neurol . 1997; 41: 716–721.
22.
Greenberg SM, Vonsattel JP, Segal AZ, et al. Association of apolipoprotein E ε2 and vasculopathy in cerebral amyloid angiopathy. Neurology . 1998; 50: 961–965.
23.
Greenberg SM, Vonsattel J-PG. Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy. Stroke . 1997; 28: 1418–1422.
24.
McCarron MO, Nicoll JA. High frequency of apolipoprotein E epsilon 2 allele is specific for patients with cerebral amyloid angiopathy-related haemorrhage. Neurosci Lett . 1998; 247: 45–48.
25.
Greenberg SM, Edgar MA. Case records of the Massachusetts General Hospital, case 22-1996. N Engl J Med . 1996; 335: 189–196.
26.
Greenberg SM, O’Donnell HC, Schaefer PW, Kraft E. MRI detection of new hemorrhages: potential marker of progression in cerebral amyloid angiopathy. Neurology . 1999; 53: 1135–1138.
27.
O’Donnell HC, Rosand J, Knudsen KA, et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med . 2000; 342: 240–245.
28.
McCarron MO, Nicoll JA, Ironside JW, Love S, Alberts MJ, Bone I. Cerebral amyloid angiopathy-related hemorrhage. Interaction of APOE ε2 with putative clinical risk factors. Stroke . 1999; 30: 1643–1646.
29.
McCarron MO, Nicoll JA, Stewart J, et al. The apolipoprotein E ε2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhage. J Neuropathol Exp Neurol . 1999; 58: 711–718.
30.
Alberts MJ, Graffagnino C, McClenny C, et al. ApoE genotype and survival from intracerebral haemorrhage. Lancet . 1995; 346: 575.
31.
McCarron MO, Muir KW, Weir CJ, et al. The apolipoprotein E ε4 allele and outcome in cerebrovascular disease. Stroke . 1998; 29: 1882–1887.
32.
Radberg JA, Olsson JE, Radberg CT. Prognostic parameters in spontaneous intracerebral hematomas with special reference to anticoagulant treatment. Stroke . 1991; 22: 571–576.
33.
Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med . 1994; 154: 1449–1457.
Information & Authors
Information
Published In
Copyright
© 2000.
Publication History
Received: February 29, 2000
Accepted: June 5, 2000
Published online: October 10, 2000
Published in print: October 10, 2000
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Cerebral Amyloid Angiopathy (CAA), Dispatches from the Land of Alzheimer's, (123-126), (2024).https://doi.org/10.1017/9781009430067.031
- Oral anticoagulant therapy in older adults, Thrombosis Research, 238, (1-10), (2024).https://doi.org/10.1016/j.thromres.2024.04.009
- Acute Hemorrhagic Stroke and Neurocritical Care, Principles and Practice of Neurocritical Care, (697-712), (2024).https://doi.org/10.1007/978-981-99-8059-8_52
- Diagnosis and Management of Cerebral Small Vessel Disease, CONTINUUM: Lifelong Learning in Neurology, 29, 2, (501-518), (2023).https://doi.org/10.1212/CON.0000000000001232
- Analyse zur Häufigkeit einer gerinnungshemmenden Medikation bei Patientinnen mit kognitiven Störungen und zerebraler Amyloidangiopathie (CAA)Analysis of the prevalence of anticoagulant therapy in patients with cognitive disorders and cerebral amyloid angiopathy (CAA), Der Nervenarzt, 95, 2, (146-151), (2023).https://doi.org/10.1007/s00115-023-01547-8
- Impact of Cerebral Microbleeds in Stroke Patients with Atrial Fibrillation, Annals of Neurology, 94, 1, (61-74), (2023).https://doi.org/10.1002/ana.26642
- The Impact of Cerebral Amyloid Angiopathy on Functional Outcome of Patients Affected by Spontaneous Intracerebral Hemorrhage Discharged from Intensive Inpatient Rehabilitation: A Cohort Study, Diagnostics, 12, 10, (2458), (2022).https://doi.org/10.3390/diagnostics12102458
- Irregular shape as an independent predictor of prognosis in patients with primary intracerebral hemorrhage, Scientific Reports, 12, 1, (2022).https://doi.org/10.1038/s41598-022-12536-3
- Assessment of CT for the categorization of hemorrhagic stroke (HS) and cerebral amyloid angiopathy hemorrhage (CAAH): A review, Biocybernetics and Biomedical Engineering, 42, 3, (888-901), (2022).https://doi.org/10.1016/j.bbe.2022.07.001
- Genetic Basis of Stroke Occurrence, Prevention, and Outcome, Stroke, (237-246.e4), (2022).https://doi.org/10.1016/B978-0-323-69424-7.00019-3
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.